Sangamo Therapeutics Inc. (SGMO) - Market Cap to Net Income Ratio

Sangamo BioSciences - graphic logo of issuer SGMO

This chart of the market valuation for Sangamo Therapeutics (SGMO) on GURU.Markets, where the indicator stands at -0.60, is based on strict control of biomaterial logistics via verified air carriers. Sangamo Therapeutics relies on a unique "zinc finger" method for targeted DNA correction in the brain and liver. Successful trials of Fabry disease treatments and tranches from pharmaceutical behemoths are driving the increase in value.

Sangamo Therapeutics, Inc. (SGMO): Price to Earnings Ratio from 07/04/2022 to 05/09/2026

Analytical breakdowns for Sangamo Therapeutics (SGMO)

General company analysis:Sangamo Therapeutics, Inc., SGMO
Original product of Sangamo BioSciences

Sangamo Therapeutics (SGMO) integrates strict bioethical standards and ESG principles into the development of DNA therapies, which impacts its operating expense structure. The P/E ratio reflects the stock's market value relative to net income, measuring the investment payback period at current earnings levels. High values signal inflated growth expectations, while low values indicate undervaluation or inherent risks. By analyzing the company's price-to-earnings ratio, an investor determines the fairness of the current market valuation.

Key competitors

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|Price to Earnings Ratio SRPT|twistbioscience.com (TWST) - Business Payback Period|P/E Multiple TXG|NTLA (Intellia) - Company Value to Net Income|Price to Earnings Ratio Stoke STOK|BioLife (BLFS) - Market Cap to Earnings|wavelifesciences.com - P/E Multiple|Market Cap to Net Income MAZE|SION: P/E Multiple|PRME - Business Payback Period|Price to Earnings Ratio TSHA|QURE - Market Cap to Net Income Ratio|P/E Multiple MGTX|Business Payback Period regenxbio.com|P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Earnings Multiple|PACB - Price to Earnings Ratio|Benitec (BNTC) - Price to Earnings Ratio|DSGN: P/E Multiple|RCKT: Market Price to Net Income Ratio|FDMT (4D Molecular Therapeutics, Inc.) - P/E Multiple|lexeotx.com (LXEO) - Business Payback Period|P/E Multiple KRRO|Price to Earnings Ratio Editas Medicine, Inc. EDIT|Price to Earnings Ratio silence-therapeutics.com SLN|PRQR: Price to Earnings Multiple|CDXS - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio